DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,487 | +45.4% | 26,150 | +40.6% | 0.01% | +25.0% |
| Q2 2023 | $4,462 | -99.8% | 18,593 | +66.5% | 0.00% | +33.3% |
| Q3 2022 | $2,884,000 | -36.9% | 11,167 | -28.3% | 0.00% | -25.0% |
| Q1 2022 | $4,570,000 | +126.7% | 15,582 | +154.2% | 0.00% | +100.0% |
| Q4 2021 | $2,016,000 | +576.5% | 6,130 | +362.6% | 0.00% | +100.0% |
| Q1 2021 | $298,000 | -88.9% | 1,325 | -89.0% | 0.00% | -66.7% |
| Q4 2020 | $2,675,000 | +809.9% | 12,043 | +780.3% | 0.00% | – |
| Q3 2020 | $294,000 | +382.0% | 1,368 | +206.0% | 0.00% | – |
| Q1 2020 | $61,000 | -85.0% | 447 | -83.2% | 0.00% | -100.0% |
| Q4 2019 | $408,000 | -54.4% | 2,664 | -70.6% | 0.00% | -75.0% |
| Q2 2018 | $895,000 | +665.0% | 9,075 | +503.0% | 0.00% | -50.0% |
| Q3 2016 | $117,000 | -56.2% | 1,505 | -47.8% | 0.01% | -61.9% |
| Q4 2015 | $267,000 | -40.4% | 2,882 | -45.2% | 0.02% | -36.4% |
| Q3 2015 | $448,000 | +61.7% | 5,258 | +61.1% | 0.03% | +3.1% |
| Q1 2015 | $277,000 | -39.7% | 3,263 | -39.1% | 0.03% | -42.9% |
| Q4 2014 | $459,000 | – | 5,357 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |